Home > Boards > US Listed > Biotechs >

Sepracor, Inc. (SEPR)

Add SEPR Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 10/22/2009 1:16:53 PM - Followers: 0 - Board type: Free - Posts Today: 0

http://www.sepracor.com/ http://finance.yahoo.com/q/ks?s=SEPR http://www.form4oracle.com/company?cik=0000877357&ticker=sepr http://moneycentral.msn.com/ownership?Symbol=SEPR Sepracor, Inc. engages in the research, discovery, development, and commercialization of pharmaceutical products for the treatment of respiratory and central nervous system disorders in the United States and Canada. It develops products for the synthesis and separation of pharmaceutical and biopharmaceutical compounds. The company markets XOPENEX (levalbuterol HCl) Inhalation Solution for the treatment of bronchospasm; XOPENEX HFA (levalbuterol tartrate) Inhalation Aerosol, a hydrofluoroalkane metered-dose inhaler for the treatment of bronchospasm; and LUNESTA (eszopiclone) for the treatment of insomnia. It also offers BROVANA (arformoterol tartrate) Inhalation Solution, a long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. Sepracor's out-licensing agreements include Schering-Plough for CLARINEX (desloratadine); sanofi-aventis for ALLEGRA (fexofenadine HCl); and UCB Pharma for XYZAL/XUSALTM (levocetirizine). It has other compounds in early stages of development for the treatment of central nervous system disorders, including Parkinson's disease and depression. The company's pipeline products comprise SEP-225289, under Phase I studies, is a serotonin, norepinephrine, and dopamine reuptake inhibitor for the treatment of major depressive disorder; SEP-227162, a serotonin and norepinephrine reuptake inhibitor for the treatment of depression and anxiety, is under Phase I clinical study; and SEP-226330 for central nervous system disorders, such as Parkinson's disease. Sepracor offers its products to primary care physicians, allergists, pulmonologists, pediatricians, hospitals, psychiatrists, and sleep specialists through its sales professionals. The company was founded in 1984 and is headquartered in Marlborough, Massachusetts.
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#20   Japanese pharmaceutical giant Dainippon Sumitomo Pharma Co. has mlkrborn 10/22/09 01:16:52 PM
#19   Dainippon of Japan acquires US drug maker Sepracor surf1944 09/03/09 07:19:47 AM
#18   Sepracor sees FDA filing by late 2008, early 2009 surf1944 09/25/08 12:33:03 AM
#17   LUNESTA(R) Next-Day Function and Discontinuation Data from a surf1944 09/03/08 08:20:17 AM
#16   Sepracor Pharma Range-Bound surf1944 08/23/08 11:13:39 AM
#15   Sepracor Announces Senior Management Appointments surf1944 08/23/08 11:13:28 AM
#14   Sepracor Announces Full Support of PhRMA's Revised Code surf1944 07/14/08 08:33:40 AM
#13   LUNESTA(R) Study of Patients with Insomnia and Co-Morbid surf1944 05/13/08 03:19:25 PM
#12   Susquehanna Lowers Sepracor Rating surf1944 04/03/08 10:41:48 PM
#11   Sepracor Cuts 2008 Earnings Guidance surf1944 03/02/08 10:19:50 AM
#10   AP Sepracor Partners to Sell Epilepsy Drug surf1944 01/09/08 07:25:33 PM
#9   Strong Volume Gainers (SEPR) surf1944 10/30/07 10:27:51 PM
#8   Oversold with an Improving RSI (SEPR) surf1944 10/23/07 09:01:30 PM
#7   http://www.businessweek.com/investor/content/oct2007/pi2007105_564105.htm?campai surf1944 10/12/07 10:25:24 PM
#6   Bullish Engulfing Patterns (SEPR) surf1944 08/20/07 10:39:40 PM
#5   Booo CPTMatt 08/10/07 08:27:41 AM
#4   Parabolic SAR Buy Signals (SEPR) from nightly stockcharts.com scan surf1944 08/09/07 07:37:26 PM
#3   What the heck? You deleted my post? CPTMatt 07/27/07 04:49:14 PM
#2   Time to look at SEPR again: surf1944 07/27/07 04:45:41 PM
Consent Preferences